Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

CymaBay Therapeutics, Inc.

CBAY•NASDAQ
Healthcare
Biotechnology
$32.48
$0.010(0.03%)
U.S. Market opens in 16h 15m

CymaBay Therapeutics, Inc. (CBAY) Stock Overview

Explore CymaBay Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap3.7B
P/E Ratio-32.74
EPS (TTM)$-0.99
ROE-0.64%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$78.28

CBAY Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of CymaBay Therapeutics, Inc. (CBAY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $78.28.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -32.74 and a market capitalization of 3.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
0.03%
3-Month Change
32.57%
6-Month Change
138.65%
Year-to-Date (YTD) Change
36.99%
1-Year Change
215.95%
3-Year Change
678.90%
5-Year Change
169.54%
All-Time (Max) Change
260.89%

Contact Information

https://www.cymabay.com
510 293 8800
7575 Gateway Boulevard, Newark, CA, 94560

Company Facts

1,010 Employees
IPO DateFeb 3, 2014
CountryUS

Frequently Asked Questions